Gail V Matthews

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. pmc Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort
    Katherine R Smith
    Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney, Sydney, NSW 2145, Australia
    Genome Med 3:57. 2011
  2. pmc Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C
    G V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 48:650-8. 2009
  3. ncbi request reprint HIV and hepatitis C coinfection
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    J Gastroenterol Hepatol 23:1000-8. 2008
  4. ncbi request reprint Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 20:863-70. 2006
  5. ncbi request reprint The management of HIV and hepatitis B coinfection
    Gail Matthews
    Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, Sydney, New South Wales, Australia
    Curr Opin Infect Dis 20:16-21. 2007
  6. ncbi request reprint Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir
    Gail V Matthews
    HIV Immunology Infectious Diseases Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 12:119-22. 2007
  7. doi request reprint A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, Sydney, NSW, Australia
    Hepatology 48:1062-9. 2008
  8. pmc Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, UNSW, Sydney, Australia
    AIDS 23:1707-15. 2009
  9. ncbi request reprint Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection
    Jason Grebely
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales UNSW, Sydney, Australia
    AIDS 26:1653-61. 2012
  10. pmc Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection
    Maryam Alavi
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    J Gastroenterol Hepatol 27:957-65. 2012

Detail Information

Publications33

  1. pmc Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort
    Katherine R Smith
    Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney, Sydney, NSW 2145, Australia
    Genome Med 3:57. 2011
    ..In people of European ancestry, there are 6 common (more than 1%) haplotypes for IL28B, one tagged by the rs8099917 minor allele, four tagged by rs12979860...
  2. pmc Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C
    G V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 48:650-8. 2009
    ..Enrollment is open to both human immunodeficiency virus (HIV)-infected and -uninfected individuals. The aim of this article was to evaluate characteristics and virological outcomes among HIV-infected individuals enrolled in ATAHC...
  3. ncbi request reprint HIV and hepatitis C coinfection
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    J Gastroenterol Hepatol 23:1000-8. 2008
    ..New therapies, including HCV protease and polymerase inhibitors, are in development and may widen therapeutic options for HIV-HCV-coinfected individuals into the future...
  4. ncbi request reprint Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    AIDS 20:863-70. 2006
    ..Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy...
  5. ncbi request reprint The management of HIV and hepatitis B coinfection
    Gail Matthews
    Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, Sydney, New South Wales, Australia
    Curr Opin Infect Dis 20:16-21. 2007
    ..This review highlights the most important recent developments in the management of HIV and hepatitis B virus coinfection...
  6. ncbi request reprint Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir
    Gail V Matthews
    HIV Immunology Infectious Diseases Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 12:119-22. 2007
    ..The safety and efficacy of tenofovir in HIV/HBV cirrhosis has not been previously described...
  7. doi request reprint A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
    Gail V Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, Sydney, NSW, Australia
    Hepatology 48:1062-9. 2008
    ..Hepatitis B e antigen (HBeAg) loss was observed in 33% of HBeAg-positive subjects, and 8% experienced hepatitis B surface antigen loss. Hepatic flare was observed in 25% of subjects...
  8. pmc Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, UNSW, Sydney, Australia
    AIDS 23:1707-15. 2009
    ..To determine if highly active antiretroviral therapy (HAART) with combination anti-hepatitis B virus (HBV) therapy compared to HAART with HBV monotherapy leads to greater HBV DNA suppression in an HIV/HBV coinfected cohort...
  9. ncbi request reprint Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection
    Jason Grebely
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales UNSW, Sydney, Australia
    AIDS 26:1653-61. 2012
    ..This study evaluated early virological decline during recent HCV therapy in HIV-uninfected individuals receiving pegylated interferon (PEG-IFN) monotherapy and HIV-infected individuals receiving PEG-IFN/RBV...
  10. pmc Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection
    Maryam Alavi
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    J Gastroenterol Hepatol 27:957-65. 2012
    ..Data on the effect of HCV treatment on mental health among injecting drug users (IDUs) are limited. We assessed mental health during treatment of recently acquired HCV, within a predominantly IDU population...
  11. pmc Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    J Hepatol 55:76-85. 2011
    ..We assessed 80/80 adherence (≥80% of PEG-IFN doses, ≥80% treatment), on-treatment adherence, and treatment completion in a study of treatment of recent HCV infection (ATAHC)...
  12. pmc Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
    Jason Grebely
    National Centre in HIV Epidemiology and Clinical Research NCHECR, University of New South Wales UNSW, Sydney, Australia
    Hepatology 52:1216-24. 2010
    ..Early therapeutic intervention could be recommended for individuals with unfavorable IL28B genotypes...
  13. pmc Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals
    Gail V Matthews
    Kirby Institute, University of New South Wales, Sydney, Australia
    PLoS ONE 8:e61297. 2013
    ..The aim of this study was to examine serological change including quantitative biomarkers in HIV-HBV coinfected patients initiating HBV active antiretroviral therapy (ART)...
  14. pmc Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection
    Jason Grebely
    Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    Hepatology 55:1058-69. 2012
    ..Conclusion: Reinfection and superinfection can occur during treatment of recent HCV and are associated with poor social functioning and ongoing IDU. ALT levels may be a useful clinical marker of reexposure...
  15. pmc Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus
    Gail V Matthews
    The Kirby Institute, University of New South Wales, Sydney, NSW 2010, Australia
    Clin Infect Dis 56:e87-94. 2013
    ..We determined the patterns and factors associated with detectable HBV DNA in HIV-HBV-coinfected subjects on highly active antiretroviral therapy (HAART)...
  16. pmc Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection
    Jason Grebely
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    Hepatology 57:2124-34. 2013
    ..hepatology 2013;)...
  17. pmc Effective treatment of injecting drug users with recently acquired hepatitis C virus infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Gastroenterology 138:123-35.e1-2. 2010
    ..We evaluated the efficacy of treatment of recent HCV infection in IDUs with acute and early chronic HCV...
  18. pmc Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
    Anchalee Avihingsanon
    The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
    AIDS Res Ther 9:6. 2012
    ..abstract:..
  19. doi request reprint Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression
    David M Iser
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Melbourne, Australia
    AIDS 25:197-205. 2011
    ....
  20. doi request reprint Treatment of acute HCV infection
    Jason Grebely
    Viral Hepatitis Clinical Research Program, National Center in HIV Epidemiology and Clinical Research, University of New South Wales, Corner Boundary and West Streets, Darlinghurst, Sydney, NSW 2010, Australia
    Nat Rev Gastroenterol Hepatol 8:265-74. 2011
    ..This Review highlights current knowledge of the epidemiology, diagnosis, natural history and treatment of acute HCV infection, including proposed recommendations for the assessment and treatment of this infection...
  21. doi request reprint Future of hepatitis C therapy: development of direct-acting antivirals
    Gregory J Dore
    Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales, Australia
    Curr Opin HIV AIDS 6:508-13. 2011
    ....
  22. doi request reprint Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia
    Fengyi Jin
    National Centre in HIV Epidemiology and Clinical Research, Level 2, 376 Victoria Street, Darlinghurst, NSW 2010, Australia
    Sex Transm Infect 86:25-8. 2010
    ..We report prevalence, incidence and risk factors for HCV infection in community-based cohorts of HIV-negative and HIV-positive homosexual men in Sydney...
  23. pmc Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C
    G V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    Clin Infect Dis 52:803-11. 2011
    ..The extent to which these separate epidemics overlap is unknown...
  24. pmc Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study
    J Grebely
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    Drug Alcohol Depend 107:244-9. 2010
    ..Decisions about whether to initiate treatment for recently acquired HCV were mainly driven by clinical factors, rather than factors related to sociodemographics or injecting behaviors...
  25. doi request reprint Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa
    Gail V Matthews
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    AIDS 25:1727-35. 2011
    ..To examine HIV and hepatitis B virus (HBV)-related outcomes in HIV/HBV-coinfected participants in the PHIDISA II study by use of HBV-active vs. non-HBV-active antiretroviral therapy (ART)...
  26. ncbi request reprint Treatment for hepatitis C virus infection among current injection drug users in Australia
    Gail Matthews
    Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, Australia
    Clin Infect Dis 40:S325-9. 2005
    ..Further studies are under way to examine outcomes of treatment for HCV among clients undergoing treatment for drug dependency who have chronic HCV infection and among current IDUs with acute and newly acquired HCV infection...
  27. pmc Invasive amebiasis in men who have sex with men, Australia
    Damien Stark
    St Vincent s Hospital, Darlinghurst, New South Wales, Australia
    Emerg Infect Dis 14:1141-3. 2008
    ..e., Japan, Taiwan, and Republic of Korea. We report locally acquired invasive amebiasis in Sydney, Australia, exclusively in MSM...
  28. ncbi request reprint ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response
    Jacinta A Holmes
    St Vincent s Hospital, University of Melbourne, Melbourne, Vic, Australia Department of Medicine, University of Melbourne, Melbourne, Vic, Australia
    Hepatology 59:2152-60. 2014
    ..Our data suggest that the relationship between Hb decline and SVR is not mechanistic, but is linked to RBV levels. (Hepatology 2014;59:2152-2160). ..
  29. ncbi request reprint Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial
    Amit C Achhra
    The Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia
    PLoS ONE 9:e99530. 2014
    ..Regimens sparing RATE (ritonavir, abacavir, tenofovir, efavirienz) agents might have better long-term safety. We conducted a feasibility exercise to assess the potential for a randomised trial evaluating RATE-sparing regimens...
  30. ncbi request reprint Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al
    Gail V Matthews
    AIDS 21:2112-3. 2007
  31. ncbi request reprint Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals
    Peter A Revill
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
    AIDS 21:1701-10. 2007
    ..To test this hypothesis, we have analysed genome-length sequences of HBV DNA from patients both prior to and during antiviral therapy...
  32. ncbi request reprint Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'
    Gail V Matthews
    AIDS 21:777-8. 2007
  33. ncbi request reprint Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
    Gail V Matthews
    Department of HIV Medicine, Chelsea Hospital, London, UK
    AIDS 16:53-61. 2002
    ....